...
首页> 外文期刊>Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology >Establishment of a DGK theta Endogenous Promoter Luciferase Reporter HepG2 Cell Line for Studying the Transcriptional Regulation of DGK theta Gene
【24h】

Establishment of a DGK theta Endogenous Promoter Luciferase Reporter HepG2 Cell Line for Studying the Transcriptional Regulation of DGK theta Gene

机译:建立DGKθ内源启动子荧光素酶报告器Hepg2细胞系,用于研究DGKθ基因的转录调控

获取原文
获取原文并翻译 | 示例
           

摘要

DGK theta protein expression levels are closely related to the development of diseases including diabetes, cancer, and neuronal disease. To investigate the transcriptional regulation of the DGK theta gene, we used CRISPR/Cas9 to generate a DGK theta endogenous promoter luciferase reporter HepG2 cell line, in which the endogenous DGK theta promoter controls the expression of the luciferase reporter gene. To test the cell line, FXR, the transcription factor for upregulating the expression of DGK theta gene, was used to validate the cell line. Furthermore, the reported agonists for the expression of DGK theta, cAMP and GW4064, the known inhibitor for DGK theta enzyme activity, R59949, and a potential regulator for DGK theta enzyme expression, EGCG (the major catechin in green tea), were applied to the reporter cell line. The results indicated that these reagents could significantly regulate the expression of reporter luciferase. Finally, four transcription factors (E2F1, c-Myc, USF1, and Bmal1) potentially binding to the DGK theta gene's upstream promoter region were tested. DGK theta expression was upregulated by c-Myc and downregulated by E2F1, which was also confirmed in wild-type HepG2 cells. We found that the cell line's luciferase activity was directly correlated with DGK theta endogenous promoter activity, suggesting that it is liable and sensitive for studying DGK theta transcriptional regulation. The study provides a useful tool for high-throughput drug screening for the treatment of DGK theta-involved diseases.
机译:DGK Theta蛋白表达水平与疾病的发展密切相关,包括糖尿病,癌症和神经元疾病。为了研究DGKθ基因的转录调节,我们使用CRISPR / CAS9生成DGKθ内源启动子荧光素酶报告器HepG2细胞系,其中内源性DGKθ启动子控制荧光素酶报告基因的表达。为了测试细胞系,FXR,用于上调DGKθ基因表达的转录因子,用于验证细胞系。此外,报告的激动剂用于表达DGK Theta,CAMP和GW4064,DGK THETA酶活性的已知抑制剂,R59949和DGK THETA酶表达的潜在调节剂,EGCG(绿茶中的主要儿茶素),记者细胞系。结果表明,这些试剂可以显着调节报告荧光素酶的表达。最后,测试了四种转录因子(E2F1,C-MYC,USF1和BMA1)潜在地与DGKθ基因的上游启动子区域结合。 DGK Theta表达由C-MYC上调,并通过E2F1下调,该E2F1也在野生型HepG2细胞中证实。我们发现,细胞系的荧光素酶活性与DGKθ内源性启动子活性直接相关,表明它对研究DGKθ转录调节是令致命和敏感的。该研究为高通量药物筛查提供了一种有用的工具,用于治疗DGK遗传症疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号